Skip to content

US · OFIX · MEDICAL - DEVICES

Orthofix Medical Inc. (OFIX) intrinsic value and stock valuation

$6.07as of 2026-11-21 · Mkt cap 415.53M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Orthofix Medical Inc. DCF and intrinsic value

InvestorsCraft values OFIX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OFIX’s statements →

Orthofix Medical Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Lewisville, TX 75056 orthofix.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$822.3M+15.1% 5y CAGRd
20112025
Net income
-$-92.19M
20112025
Free cash flow
-$-1.28M
20112025
Total equity
$450M+4.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$822.3M$799.5M$746.6M$460.7M$464.5M
Operating income-$-68.47M-$-84.62M-$-139.11M-$-13.27M-$-8.31M
Net income-$-92.19M-$-126M-$-151.4M-$-19.75M-$-38.38M
EPSd-$-2.31M-$-3.3M-$-4.12M-$-982.59K-$-1.95M
Operating cash flow$33.4M$25.8M-$-45.75M-$-11.54M$18.5M
Capital expenditure-$-34.63M-$-34.88M-$-62.05M-$-23.16M-$-19.59M
Free cash flow-$-1.28M-$-9.09M-$-107.8M-$-34.7M-$-1.12M
Total assets$850.7M$893.3M$925.3M$458.6M$476.6M
Total debt$229.3M$179.6M$117.1M$21.5M$24.3M
Net debt$147.2M$96.4M$84M-$-29.17M-$-63.53M
Total equity$450M$503.1M$598.7M$336.9M$336.9M
Cash and short-term investments$82M$83.2M$33.1M$50.7M$87.9M
Income statement
20252024202320222021
Revenue$822.3M$799.5M$746.6M$460.7M$464.5M
Cost of revenue$270.6M$253.6M$260.4M$123.5M$114.9M
Gross profit$551.7M$545.9M$486.3M$337.2M$349.6M
Research and development expenses$57.1M$73.6M$80.2M$49.1M$49.6M
Selling, general and administrative expenses$456.4M$532.5M$530.4M$308.8M$290.7M
Other expenses$106.7M$24.3M$14.8M-$-7.4M$17.6M
Operating expenses$620.2M$630.5M$625.4M$350.4M$357.9M
Cost and expenses$890.8M$884.1M$885.8M$474M$472.8M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$17.5M$29.6M$8.63M$1.29M$1.84M
Depreciation and amortization$51M$60.1M$60.6M$32.1M$33.1M
Ebitda-$-22.35M-$-34.18M-$-79.49M$15.7M$21.4M
Operating income-$-68.47M-$-84.62M-$-139.11M-$-13.27M-$-8.31M
Total other income/expenses, net-$-22.34M-$-39.26M-$-9.57M-$-4.44M-$-5.18M
Income before tax-$-90.81M-$-123.88M-$-148.68M-$-17.71M-$-13.49M
Income tax expense$1.38M$2.12M$2.72M$2.04M$24.9M
Net income-$-92.19M-$-126M-$-151.4M-$-19.75M-$-38.38M
Weighted average shares outstanding$39.9M$38.1M$36.7M$20.1M$19.7M
Weighted average diluted shares outstanding$39.9M$38.1M$36.7M$20.1M$19.7M
Balance sheet
20252024202320222021
Cash and short-term investments$82M$83.2M$33.1M$50.7M$87.9M
Net receivables$135.8M$134.7M$128.1M$82.9M$78.6M
Inventory$34.2M$189.5M$222.2M$100.2M$83M
Total current assets$416.9M$433.3M$420.4M$256M$269.5M
Property, plant and equipment, net-$-11.09M$139.8M$159.1M$58.2M$59.3M
Goodwill and intangible assets$267.7M$293.7M$312.4M$118.7M$124M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$433.8M$460M$504.9M$202.6M$207.1M
Total assets$850.7M$893.3M$925.3M$458.6M$476.6M
Accounts payable$58.4M$48.8M$58.4M$27.6M$26.5M
Short-term debt$3.98M$4.78M$5.43M$2.29M$4.42M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$170.5M$168.6M$165.2M$83.6M$105.8M
Long-term debt$225.3M$174.9M$111.6M$19.2M$19.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$230.1M$221.5M$161.4M$38.2M$33.9M
Capital lease obligations$42.5M$22.6M$22.7M$21.5M$24.3M
Total liabilities$400.6M$390.2M$326.6M$121.8M$139.7M
Common stock$3.98M$3.85M$3.72M$2.02M$1.98M
Retained earnings-$-368.33M-$-276.14M-$-150.14M$1.25M$21M
Accumulated other comprehensive income (loss)$620K-$-4.3M-$-1.29M-$-1.38M$0.00
Total equity$450M$503.1M$598.7M$336.9M$336.9M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$229.3M$179.6M$117.1M$21.5M$24.3M
Net debt$147.2M$96.4M$84M-$-29.17M-$-63.53M
Cash flow statement
20252024202320222021
Net income-$-92.19M-$-126M-$-151.4M-$-19.75M-$-38.38M
Depreciation and amortization$83.3M$76M$60.6M$32.1M$33.1M
Stock-based compensation$28.7M$32.5M$35.7M$18.4M$15.4M
Change in working capital-$-21.5M-$-19.25M-$-53.96M-$-29.23M-$-18.1M
Accounts receivable-$-1.58M-$-9.53M-$-10.41M-$-6.74M-$-7.05M
Inventory-$-10.75M-$-5.55M-$-58.05M-$-18.13M$620K
Accounts payable$2.6M-$-5.57M$8.64M$2.28M$4.25M
Net cash provided by operating activities$33.4M$25.8M-$-45.75M-$-11.54M$18.5M
Investments in property, plant and equipment-$-34.63M-$-34.88M-$-62.05M-$-23.16M-$-19.59M
Acquisitions, net$0.00$0.00$29.4M-$-1.5M$0.00
Net cash used for investing activities-$-34.6M-$-27.58M-$-33.13M-$-24.53M-$-23.01M
Common stock issued$5.93M$6.26M$5.13M$4.34M$8.82M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-790K$50.7M$65.3M-$-80K-$-3.62M
Net change in cash-$-620K$48M-$-12.94M-$-37.15M-$-8.97M
Cash at end of period$85.1M$85.7M$37.8M$50.7M$87.9M
Operating cash flow$33.4M$25.8M-$-45.75M-$-11.54M$18.5M
Capital expenditure-$-34.63M-$-34.88M-$-62.05M-$-23.16M-$-19.59M
Free cash flow-$-1.28M-$-9.09M-$-107.8M-$-34.7M-$-1.12M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Orthofix Medical Inc.

        Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

        CEO
        Massimo Calafiore
        Employees
        1.61K
        Beta
        0.71

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Orthofix Medical Inc. (OFIX)?

        Orthofix Medical Inc. (OFIX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is OFIX undervalued?

        OFIX trades at a price of $6.07 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.